Aurora Cannabis (TSE:ACB) Stock Price Up 0.8% – What’s Next?

Aurora Cannabis Inc. (TSE:ACB) was up 0.8% during mid-day trading on Tuesday . The company traded as high as C$4.01 and last traded at C$3.91. Approximately 677,940 shares traded hands during mid-day trading, an increase of 71% from the average daily volume of 395,573 shares. The stock had previously closed at C$3.88.

Wall Street Analyst Weigh In

A number of analysts have recently commented on ACB shares. TD cut their price objective on shares of Aurora Cannabis from C$10.00 to C$8.00 and set a “buy” rating on the stock in a research report on Friday, June 12th. Canaccord Genuity Group decreased their target price on shares of Aurora Cannabis from C$6.50 to C$5.00 and set a “buy” rating for the company in a research report on Tuesday, June 30th. Three investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Aurora Cannabis presently has an average rating of “Buy” and a consensus target price of C$7.17.

Aurora Cannabis Price Performance

The stock has a market cap of C$242.19 million, a price-to-earnings ratio of -1.83 and a beta of 0.27. The company has a debt-to-equity ratio of 4.66, a quick ratio of 2.48 and a current ratio of 5.94. The company has a 50-day simple moving average of C$4.13 and a two-hundred day simple moving average of C$4.66.

Aurora Cannabis (TSE:ACB) last released its quarterly earnings data on Thursday, June 11th. The company reported C($0.99) EPS for the quarter. Aurora Cannabis had a negative net margin of 12.13% and a negative return on equity of 7.25%. The company had revenue of C$38.01 million during the quarter. As a group, equities research analysts forecast that Aurora Cannabis Inc. will post -0.22 EPS for the current year.

About Aurora Cannabis

Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael ’71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries.